Evidence map›Paper›PMID 35448721›Full record

ArticleTomography (Ann Arbor, Mich.)2022

Different Prognostic Values of Dual-Time-Point FDG PET/CT Imaging Features According to Treatment Modality in Patients with Non-Small Cell Lung Cancer.

Su Jin Jang, Jeong Won Lee, Ji-Hyun Lee, In Young Jo, Sang Mi Lee

Abstract read
In one paragraph

Article in Tomography (Ann Arbor, Mich.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Su Jin JangDepartment of Nuclear Medicine, CHA Bundang Medical Center, CHA University, 59 Yatap-ro, Bundang-gu, Seongnam 13496, Korea.
Jeong Won LeeDepartment of Nuclear Medicine, International St. Mary's Hospital, Catholic Kwandong University, Simgok-ro 100 gil 25, Seo-gu, Incheon 22711, Korea.ORCID 0000-0002-2697-3578
Ji-Hyun LeeDepartment of Pulmonology, Allergy and Critical Care Medicine, CHA Bundang Medical Center, CHA University, 59 Yatap-ro, Bundang-gu, Seongnam 13496, Korea.ORCID 0000-0002-8287-5470
In Young JoDepartment of Radiation Oncology, Soonchunhyang University Cheonan Hospital, 31 Suncheonhyang 6 gil, Dongnam-gu, Cheonan 31151, Korea.
Sang Mi LeeDepartment of Nuclear Medicine, Soonchunhyang University Cheonan Hospital, 31 Suncheonhyang 6 gil, Dongnam-gu, Cheonan 31151, Korea.ORCID 0000-0002-7943-3807

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was aimed to investigate whether dual-time-point F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) imaging features had different prognostic values according to the treatment modality in patients with non-small cell lung cancer (NSCLC). We retrospectively reviewed 121 NSCLC patients with surgical resection (surgery group) and 69 NSCLC patients with chemotherapy and/or radiotherapy (CRT group), who underwent pretreatment dual-time-point FDG PET/CT. The maximum standardized uptake value (SUV), metabolic tumor volume (MTV), total lesion glycolysis (TLG), SUV histogram entropy of primary cancer, and the percent changes in these parameters (Δparameters) were measured. In multivariate analysis, MTV, TLG, and entropy on both early and delayed PET/CT scans were significantly associated with progression-free survival (PFS) in the surgery group, but all Δparameters failed to show a significant association. In the CRT group, TLG on the early PET, maximum SUV on the delayed PET, ΔMTV, and ΔTLG were significant independent predictors for PFS. In the surgery group, patients with high values of MTV, TLG, and entropy had worse survival, whereas, in the CRT group, patients with high values of ΔMTV and ΔTLG had better survival. Dual-time-point FDG PET/CT parameters showed different prognostic values between the surgery and CRT groups of NSCLC patients.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsFluorodeoxyglucose F18HumansPositron-Emission TomographyPositron Emission Tomography Computed TomographyPrognosisRadiopharmaceuticalsRetrospective StudiesFluorodeoxyglucose F18RadiopharmaceuticalsF-18 fluorodeoxyglucosenon-small cell lung cancerpositron emission tomographyprognosis

Identifiers

PMID35448721
PMCPMC9028882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.